1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global ELISA Analyzers Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.3.4. Global ELISA Analyzers Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pricing Analysis
5.2. Regulatory Scenario by Region/globally
5.3. COVID-19 Impact Analysis
6. Global ELISA Analyzers Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2017–2031
6.3.1. Automated ELISA Analyzers
6.3.2. Semi-automated ELISA Analyzers
6.4. Market Attractiveness Analysis, by Product Type
7. Global ELISA Analyzers Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Drug Development
7.3.2. Clinical Diagnosis
7.3.3. Others
7.4. Market Attractiveness Analysis, by Application
8. Global ELISA Analyzers Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Diagnostic Laboratories
8.3.2. Pharmaceutical & Biotechnology Companies
8.3.3. Contract Research Organizations
8.3.4. Others
9. Global ELISA Analyzers Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America ELISA Analyzers Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017–2031
10.2.1. Automated ELISA Analyzers
10.2.2. Semi-automated ELISA Analyzers
10.3. Market Value Forecast, by Application, 2017–2031
10.3.1. Drug Development
10.3.2. Clinical Diagnosis
10.3.3. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Diagnostic Laboratories
10.4.2. Pharmaceutical & Biotechnology Companies
10.4.3. Contract Research Organizations
10.4.4. Others
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Application
10.5.3. By End-user
10.5.4. By Country
11. Europe ELISA Analyzers Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2031
11.2.1. Automated ELISA Analyzers
11.2.2. Semi-automated ELISA Analyzers
11.3. Market Value Forecast, by Application, 2017–2031
11.3.1. Drug Development
11.3.2. Clinical Diagnosis
11.3.3. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Diagnostic Laboratories
11.4.2. Pharmaceutical & Biotechnology Companies
11.4.3. Contract Research Organizations
11.4.4. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific ELISA Analyzers Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2031
12.2.1. Automated ELISA Analyzers
12.2.2. Semi-automated ELISA Analyzers
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Drug Development
12.3.2. Clinical Diagnosis
12.3.3. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Diagnostic Laboratories
12.4.2. Pharmaceutical & Biotechnology Companies
12.4.3. Contract Research Organizations
12.4.4. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America ELISA Analyzers Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2031
13.2.1. Automated ELISA Analyzers
13.2.2. Semi-automated ELISA Analyzers
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Drug Development
13.3.2. Clinical Diagnosis
13.3.3. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Diagnostic Laboratories
13.4.2. Pharmaceutical & Biotechnology Companies
13.4.3. Contract Research Organizations
13.4.4. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa ELISA Analyzers Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017–2031
14.2.1. Automated ELISA Analyzers
14.2.2. Semi-automated ELISA Analyzers
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Drug Development
14.3.2. Clinical Diagnosis
14.3.3. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Diagnostic Laboratories
14.4.2. Pharmaceutical & Biotechnology Companies
14.4.3. Contract Research Organizations
14.4.4. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Global ELISA Analyzers Market, Company Share Analysis (2022)
15.2. Company Profiles
15.2.1. Bio-Rad Laboratories, Inc.
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Product Portfolio
15.2.1.3. Financial Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Strategic Overview
15.2.2. Merck KGaA
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Product Portfolio
15.2.2.3. Financial Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. Thermo Fisher Scientific
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Product Portfolio
15.2.3.3. Financial Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Dynex Technologies, Inc.
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Product Portfolio
15.2.4.3. Financial Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Grifols, S.A.
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Product Portfolio
15.2.5.3. Financial Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Strategic Overview
15.2.6. Tecan Group Ltd.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Product Portfolio
15.2.6.3. Financial Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Strategic Overview
15.2.7. Monobind
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Product Portfolio
15.2.7.3. Financial Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Strategic Overview
15.2.8. Transasia Bio-Medicals
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Product Portfolio
15.2.8.3. Financial Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Strategic Overview
15.2.9. MeCan Medical Equipment
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Product Portfolio
15.2.9.3. Financial Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Strategic Overview
15.2.10. CTK Biotech
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Product Portfolio
15.2.10.3. Financial Overview
15.2.10.4. SWOT Analysis
15.2.10.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
